Table 1. Characteristics of Individuals With IMIDs and Matched People Without an IMID on the Date of Positive COVID-19 Test Result.
| Characteristic | No. (%) | |
|---|---|---|
| People with any IMID (n = 28 440) | Matched people without an IMID (n = 126 437) | |
| Age, mean (SD), y | 52.1 (18.8) | 50.1 (18.0) |
| Sex | ||
| Female | 16 741 (58.9) | 73 793 (58.4) |
| Male | 11 699 (41.1) | 52 644 (41.6) |
| Rural | 936 (3.3) | 2014 (1.6) |
| Mean neighborhood income quintile | ||
| 1 (Lowest) | 6095 (21.4) | 27 179 (21.5) |
| 2 | 5794 (20.4) | 25 792 (20.4) |
| 3 | 5876 (20.7) | 26 410 (20.9) |
| 4 | 5507 (19.4) | 24 466 (19.4) |
| 5 (Highest) | 5168 (18.2) | 22 590 (17.9) |
| Previous VTE | 427 (1.5) | 866 (0.7) |
| Chronic obstructive pulmonary disease | 1286 (4.5) | 3033 (2.4) |
| Congestive heart failure | 1549 (5.4) | 3907 (3.1) |
| Diabetes | 5868 (20.6) | 21 700 (17.2) |
| Charlson Comorbidity Index, median (IQR) | 1 (0-2) | 0 (0-1) |
| Type of IMID | ||
| Ankylosing spondylitis | 1453 (5.1) | NA |
| Inflammatory bowel disease | 4331 (15.2) | NA |
| Multiple sclerosis | 1954 (6.9) | NA |
| Psoriatic arthritis | 1134 (4.0) | NA |
| Polymyalgia rheumatica | 535 (1.9) | NA |
| Psoriasis | 10 739 (37.8) | NA |
| Rheumatoid arthritis | 5883 (20.7) | NA |
| Systemic autoimmune rheumatic disease | 2506 (8.8) | NA |
| Uveitis | 3000 (10.5) | NA |
| Vasculitis | 512 (1.8) | NA |
| IMID duration | ||
| <1 y | 1115 (3.9) | NA |
| 1 to <3 y | 2762 (9.7) | NA |
| 3 to <5 y | 2695 (9.5) | NA |
| ≥5 y | 21 868 (76.9) | NA |
| No. of IMIDs | ||
| 1 | 25 479 (89.6) | NA |
| 2 | 2411(8.5) | NA |
| ≥3 | 550 (2.0) | NA |
| COVID-19 vaccination | 7704 (27.1) | 34 303 (27.1) |
| Deaths | 15 661 (5.5) | 4403 (3.5) |
Abbreviations: IMID, immune-mediated inflammatory disease; NA, not applicable; VTE, venous thromboembolism.